Adriaan W Bruijnzeel1,2,3. 1. Department of Psychiatry, University of Florida, 1149 Newell Dr., Gainesville, FL, 32611, USA. awbruijn@ufl.edu. 2. Department of Neuroscience, University of Florida, Gainesville, FL, USA. awbruijn@ufl.edu. 3. Center for Addiction Research and Education, University of Florida, Gainesville, FL, USA. awbruijn@ufl.edu.
Abstract
RATIONALE: The mildly euphoric and cognitive enhancing effects of nicotine play a role in the initiation of smoking, while dysphoria and anxiety associated with smoking cessation contribute to relapse. After the acute withdrawal phase, smoking cues, a few cigarettes (i.e., lapse), and stressors can cause relapse. Human and animal studies have shown that neuropeptides play a critical role in nicotine addiction. OBJECTIVES: The goal of this paper is to describe the role of neuropeptide systems in the initiation of nicotine intake, nicotine withdrawal, and the reinstatement of extinguished nicotine seeking. RESULTS: The reviewed studies indicate that several drugs that target neuropeptide systems diminish the rewarding effects of nicotine by preventing the activation of dopaminergic systems. Other peptide-based drugs diminish the hyperactivity of brain stress systems and diminish withdrawal-associated symptom severity. Blockade of hypocretin-1 and nociceptin receptors and stimulation of galanin and neurotensin receptors diminishes the rewarding effects of nicotine. Both corticotropin-releasing factor type 1 and kappa-opioid receptor antagonists diminish dysphoria and anxiety-like behavior associated with nicotine withdrawal and inhibit stress-induced reinstatement of nicotine seeking. Furthermore, blockade of vasopressin 1b receptors diminishes dysphoria during nicotine withdrawal, and melanocortin 4 receptor blockade prevents stress-induced reinstatement of nicotine seeking. The role of neuropeptide systems in nicotine-primed and cue-induced reinstatement is largely unexplored, but there is evidence for a role of hypocretin-1 receptors in cue-induced reinstatement of nicotine seeking. CONCLUSION: Drugs that target neuropeptide systems might decrease the euphoric effects of smoking and improve relapse rates by diminishing withdrawal symptoms and improving stress resilience.
RATIONALE: The mildly euphoric and cognitive enhancing effects of nicotine play a role in the initiation of smoking, while dysphoria and anxiety associated with smoking cessation contribute to relapse. After the acute withdrawal phase, smoking cues, a few cigarettes (i.e., lapse), and stressors can cause relapse. Human and animal studies have shown that neuropeptides play a critical role in nicotine addiction. OBJECTIVES: The goal of this paper is to describe the role of neuropeptide systems in the initiation of nicotine intake, nicotine withdrawal, and the reinstatement of extinguished nicotine seeking. RESULTS: The reviewed studies indicate that several drugs that target neuropeptide systems diminish the rewarding effects of nicotine by preventing the activation of dopaminergic systems. Other peptide-based drugs diminish the hyperactivity of brain stress systems and diminish withdrawal-associated symptom severity. Blockade of hypocretin-1 and nociceptin receptors and stimulation of galanin and neurotensin receptors diminishes the rewarding effects of nicotine. Both corticotropin-releasing factor type 1 and kappa-opioid receptor antagonists diminish dysphoria and anxiety-like behavior associated with nicotine withdrawal and inhibit stress-induced reinstatement of nicotine seeking. Furthermore, blockade of vasopressin 1b receptors diminishes dysphoria during nicotine withdrawal, and melanocortin 4 receptor blockade prevents stress-induced reinstatement of nicotine seeking. The role of neuropeptide systems in nicotine-primed and cue-induced reinstatement is largely unexplored, but there is evidence for a role of hypocretin-1 receptors in cue-induced reinstatement of nicotine seeking. CONCLUSION: Drugs that target neuropeptide systems might decrease the euphoric effects of smoking and improve relapse rates by diminishing withdrawal symptoms and improving stress resilience.
Authors: Adrie W Bruijnzeel; Ben Lewis; Lakshmi K Bajpai; Timothy E Morey; Donn M Dennis; Mark Gold Journal: Biol Psychiatry Date: 2005-09-19 Impact factor: 13.382
Authors: D H Malin; J R Lake; P Newlin-Maultsby; L K Roberts; J G Lanier; V A Carter; J S Cunningham; O B Wilson Journal: Pharmacol Biochem Behav Date: 1992-11 Impact factor: 3.533
Authors: Nicholas A Harris; Austin T Isaac; Anne Günther; Kevin Merkel; James Melchior; Michelle Xu; Eghosa Eguakun; Rafael Perez; Brett P Nabit; Stephanie Flavin; Ralf Gilsbach; Brian Shonesy; Lutz Hein; Ted Abel; Arnd Baumann; Robert Matthews; Samuel W Centanni; Danny G Winder Journal: J Neurosci Date: 2018-08-27 Impact factor: 6.167
Authors: Jean R Geste; Brandon Levin; Isaac Wilks; Marjory Pompilus; Xiping Zhang; Karyn A Esser; Marcelo Febo; Laura O'Dell; Adriaan W Bruijnzeel Journal: Nicotine Tob Res Date: 2020-02-06 Impact factor: 4.244